In
its relatively short tenure thus-far, the exploding marijuana market has
birthed numerous business opportunities for corporations and pharmaceuticals
who see revenue-generating opportunities as a result of loosened medical
marijuana laws. One of the sturdiest niches within this industry is edible
cannabis-based medicines, driven by a growing number of patients worldwide who
benefit from the therapeutic properties of cannabinoids.
The
most common oral administration of cannabinoids is through edibles such as
cookies, brownies, butter, tea, cakes and lozenges. Countless companies are
exploring this market, opening up bakeries and dispensaries offering a wide
variety of cannabis edibles.
But
because of their “confectionary” packaging, the potency of edibles made from
marijuana is unknown and often underestimated. Cannabis-infused edibles usually
contain high doses of cannabinoids, which may cause undesirable side effects
such as dizziness, anxiety and dissociation. While the oral administration of
cannabis has the longest therapeutic window (4-8 hours), the psychoactive side
effects are often a deterrent for individuals seeking therapeutic benefit
rather than a recreational high.
Cannabics
Pharmaceuticals years ago recognized this unmet need for an oral formulation
with higher bioavailabity and a lessened peak of psychoactive effect. In fact,
the company was founded in 2012 by a team of researchers in the fields of
molecular biology, cancer research and pharmacology who embarked upon a mission
to formulate a new type of oral capsule with a longer and plateaued therapeutic
window and lower psychoactive outcome.
The
company’s flagship product is Cannabics SR, an IP-pending medical cannabis capsule
designed specifically for cancer patients as a palliative care treatment. Free
of any artificial additives or chemical substances, the capsule contains a pure
concentrate of cannabinoids derived from select cannabis strains, embedded in a
sophisticated and advanced formulation. In observational studies, the Cananbics
SR capsules provided beneficial therapeutic effects for 10-12 hours upon a
single oral administration. Cannabics SR capsules have been used by certified
patients in Israel during the last year, and received highly positive and
supportive reviews from both patients and physicians.
Cannabics
Pharmaceuticals is now preparing to launch its line of SR products in eligible
states of the U.S. and EU markets under existing medical cannabis regulations.
As part of its overarching mission, the company recently secured an IP
licensing and collaboration agreement with Spain-based Kalapa Holding, which
will manufacture and distribute Cannabics SR medical cannabis products to
certified patients in the Spanish market.
Through
its research and development facility in Israel, Cannabics Pharmaceuticals
continues to develop its pipeline of advanced cannabinoid-based therapies,
leveraging collaborations with major medical centers in Israel and momentum
from its new partnership with Kalapa Holding in Europe.
While
the U.S. FDA has yet to approve even basic private research relating to
cannabis, much less FDA approval for cannabis-based edible products for
medicinal use, the environment is quite different in Israel. Within the Israeli
Ministry of Health, there is a stand-alone agency, the Israeli Medical Cannabis
Agency, (IMCA), which just last month granted Cannabics Pharmaceuticals a
government license to launch their advanced scientific R&D program at their
new state of the art laboratory for controlled & exclusive Cannabinoid
Research. With this government license and new laboratory, Cannabics
Pharmaceuticals is now set to conduct high level scientific and medical
research for the identification of novel cannabinoid based therapies, as well
as formal and controlled clinical studies in order to gauge and authenticate
the true medical benefits of these therapies. An obvious long-term goal for
these R&D programs would be the eventual FDA approval and registration as
Rx pharmaceuticals of the natural cannabinoid based therapies developed by the
company – a goal that has not yet been achieved by any pharmaceutical company
in the world.
Unlike
most current producers of edible cannabis products, Cannabis Pharmaceuticals is
focusing a substantial amount of its energies and funds not only in generating
sales, but also in the actual science of cannabinoids, with the goal of
developing novel cannabinoid based therapies for various debilitating ailments.
Given the penetrating research to date performed by the company, along with
their new R&D lab, IMCA license and upcoming clinical studies, it appears
that Cannabics Pharmaceuticals may well reach its professed goal of “being a
leading pioneer of scientifically proven medical cannabinoid pharmacology”, and
much earlier than they had even hoped for.
For
more information, visit www.cannabics.com
About QualityStocks
QualityStocks
is committed to connecting subscribers with companies that have huge potential
to succeed in the short and long-term future. We offer several ways for
investors to find, evaluate, and learn more about investing in these companies.
Sign
up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The
Quality Stocks Daily Blog http://blog.qualitystocks.net
The
Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The
Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please
see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment